Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: early in vivo cardiovascular effects.

Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: early in vivo cardiovascular effects. Eur J Pharmacol. 2018 Sep 07;: Authors: Gavazzoni M, Lombardi C, Vizzardi E, Gorga E, Sciatti E, Rossi L, Belotti A, Rossi G, Metra M, Raddino R Abstract Patients who experienced cardiovascular side effects during cancer therapy with carfilzomib for multiple myeloma had relapsed multiple myeloma, so have be previously treated with other cancer therapies. The present is a single center cohort study to evaluate early cardiovascular effects of administration of irreversible proteasome inhibitor carfilzomib in naïve patients. We included 24 patients and collected cardiovascular side effects, echocardiographic parameters and endothelial function at baseline and after 4 cycles. At early follow up we observed increase in blood arterial pressure values (mean change in systolic pressure of 10mmHg (P- value < 0.01; diastolic arterial pressure and mean arterial pressure of 3.3mmHg and 5.4mmHg, both P- value < 0.01). Reactive hyperemia PAT index was reduced in the whole cohort by a mean of 0.46 points (P -value <0.01); diastolic function was changed: E-wave-deceleration-time (EDT) was reduced by 49,96 ± 31 msec, P- value < 0.05 and early diastolic tissue Doppler velocity (e´) by a mean value of 1.46cm/sec, P - value 0.04. At early follow up we did not observe events of g...
Source: European Journal of Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Eur J Pharmacol Source Type: research